Professor Ian Frazer recalls 'lucky' discovery of cervical cancer vaccine, page-15

Re lifting the profile of cc.........

We are not asking builders to try a new brand of nail gun.......... up take by consumers will have to be a very carefully considered decision. Cc remaims a very new product with limited high level data to describe how it performs. Sure we know how it works in animals and there are a number of of small case series and sure we have thousands of cases of use (but no formal requirement to report any adverse outcomes)..... but the ultra cautious nature of cardiac surgeons may (most likely will) not swap over to cc all that easily.

Promote and raise profile....but the uptake is more dependant on user confidence....and in the absence of high level data it will be slower than some here will be happy with. Traction is being achieved....but slowly.